Literature DB >> 29185142

Initial and long term impact of a multi-disciplinary task force in the diagnosis and management of heparin-induced thrombocytopenia.

Ming Y Lim1, Joyce Foster2, Angela Rourk2, Charles S Greenberg3.   

Abstract

Many medical centers are faced with a major challenge in making an accurate diagnosis of heparin-induced thrombocytopenia (HIT) and ensuring appropriate changes in management strategy in line with guideline recommendations. We report the initial and long-term impact and challenges of institution-wide changes in the diagnosis and management of HIT in the inpatient setting at an academic medical center. We established a HIT Task Force, consisting of a multidisciplinary team of non-malignant hematologists, nursing, pharmacist, pathology, blood bank and clinical lab informatics. Changes were implemented from 2011 to 2012. In 2013, testing for PF4 and SRA decreased by 37.5 and 85%, respectively. 100% of positive PF4 received an automatic hematology consult to guide management, leading to a 78% reduction in the use of direct thrombin inhibitors. Annual audits in the subsequent years demonstrated increasing testing for HIT due to changes in the electronic ordering system. Through continuous monitoring, these shortfalls were detected and intervene early on with continued success. The implementation of a centralized hospital-wide protocol via a multidisciplinary task force that coordinates testing and treatment of patients suspected of having HIT led to a substantial reduction in PF4 and SRA testing, as well as use of DTIs, resulting in a safe and cost-effective approach for the diagnosis and treatment of HIT. Our study highlights the important of continuous monitoring to maintain the improvements made. Despite our initial success, annual re-auditing allowed for early detection of challenges, which then allowed appropriate early intervention.

Entities:  

Keywords:  Anticoagulant; Heparin; Thrombocytopenia

Mesh:

Substances:

Year:  2018        PMID: 29185142     DOI: 10.1007/s11239-017-1592-z

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  11 in total

1.  Heparin-Induced Thrombocytopenia.

Authors:  Andreas Greinacher
Journal:  N Engl J Med       Date:  2015-11-05       Impact factor: 91.245

Review 2.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Nonheparin anticoagulants for heparin-induced thrombocytopenia.

Authors:  John G Kelton; Donald M Arnold; Shannon M Bates
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

4.  The scope and value of an anticoagulation stewardship program at a community teaching hospital.

Authors:  Maura K Wychowski; Christina I Ruscio; Peter A Kouides; Ronald L Sham
Journal:  J Thromb Thrombolysis       Date:  2017-04       Impact factor: 2.300

5.  Use of a computer-based provider order entry (CPOE) intervention to optimize laboratory testing in patients with suspected heparin-induced thrombocytopenia.

Authors:  Bethany T Samuelson; Emily Glynn; Meredith Holmes; Andrew A White; Daniel B Martin; David Garcia
Journal:  Thromb Res       Date:  2015-09-08       Impact factor: 3.944

6.  Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program.

Authors:  Brianne M Ritchie; Katelyn W Sylvester; David P Reardon; William W Churchill; Nancy Berliner; Jean M Connors
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

7.  What is the potential for overdiagnosis of heparin-induced thrombocytopenia?

Authors:  Gregory K Lo; Christopher S Sigouin; Theodore E Warkentin
Journal:  Am J Hematol       Date:  2007-12       Impact factor: 10.047

8.  Heparin-induced thrombocytopenia: reducing misdiagnosis via collaboration between an inpatient anticoagulation pharmacy service and hospital reference laboratory.

Authors:  Allison E Burnett; Harmony Bowles; Matthew E Borrego; Tiffany N Montoya; David A Garcia; Charles Mahan
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

9.  A high-value cost conscious approach to minimize heparin induced thrombocytopenia antibody (HITAb) testing using the 4T score.

Authors:  Mohanad Hasan; Pannaga Malalur; Manas Agastya; Ali O Malik; Yaser Dawod; Mohammad Jaradat; Ji-Won Yoo; Ranjit Makar
Journal:  J Thromb Thrombolysis       Date:  2016-10       Impact factor: 2.300

10.  Evaluation of heparin-induced thrombocytopenia (HIT) laboratory testing and the 4Ts scoring system in the intensive care unit.

Authors:  Wesly Pierce; Joseph Mazur; Charles Greenberg; Joan Mueller; Joyce Foster; John Lazarchick
Journal:  Ann Clin Lab Sci       Date:  2013       Impact factor: 1.256

View more
  4 in total

1.  Analyzing the impact of systems-based hematologist in the healthcare system at an academic medical center.

Authors:  Ming Y Lim; Charles S Greenberg
Journal:  J Thromb Thrombolysis       Date:  2019-01       Impact factor: 2.300

Review 2.  Systems-based hematology: highlighting successes and next steps.

Authors:  Jori E May; Patrick C Irelan; Kailee Boedeker; Emily Cahill; Steven Fein; David A Garcia; Lisa K Hicks; Janice Lawson; Ming Y Lim; Colleen T Morton; Anita Rajasekhar; Satish Shanbhag; Marc S Zumberg; Robert M Plovnick; Nathan T Connell
Journal:  Blood Adv       Date:  2020-09-22

3.  4Ts Score and EuroSCORE in cardiac surgery.

Authors:  Anna Vittoria Mattioli; Antonio Manenti; Alberto Farinetti
Journal:  J Thromb Thrombolysis       Date:  2018-02       Impact factor: 2.300

4.  Improving compliance with appropriateness of testing for heparin-induced thrombocytopaenia: a quality improvement report.

Authors:  Meric Mericliler; Vera Kazakova; Diala Nicolas; Utkarsh H Acharya; Bertrand L Jaber
Journal:  BMJ Open Qual       Date:  2022-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.